A-3 Amendment 0003.pdf
PDF 299 KB Posted
- Solicitation number
- HT9402-24-Q-9304
- Issued by
-
Defense Health Agency
About this file
This document is an Amendment to Solicitation HT9402-24-Q-9304 issued by the Defense Health Agency. The purpose of the amendment is to remove Fasenra 10mg - Atopy - NA from the Request for Quotation (RFQ). All other terms and conditions remain the same.
The RFQ is for the Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement and Uniform Formulary Additional Discount Program. The RFQ includes pharmaceutical agents within Drug Classes identified for placement on the DoD Uniform Formulary. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements and Uniform Formulary Additional Discount Program Agreements based on the Pharmacy and Therapeutics (P&T) Committee's review and selection of agents for the Uniform Formulary. The P&T Committee meeting to review newly approved drugs is scheduled for August 2024. The RFQ, including the BPA and ADP appendices, and instructions for responding are provided. The pre-quotation teleconference is on July 10, 2024.
View the file
Other files
| File | Type | Posted |
|---|---|---|
| A-3 Price List - Fasenra 10mg - Respiratory Interleukins - NA.xlsx | XLSX spreadsheet | |
| A-3 Price List - Fasenra 10mg - Atopy - NA.xlsx | XLSX spreadsheet | |
| A-3 Price List - Fasenra 10mg - Atopy - NA.xlsx | XLSX spreadsheet | |
| A-3 Amendment 0002.pdf | ||
| Amendment 0001 RFQ3 NAD.pdf | ||
| A-3 Price List - Fasenra 10mg - Respiratory Interleukins - NA.xlsx | XLSX spreadsheet | |
| A-3 Price List - Myhibbin - Immunosuppressive - NA.xlsx | XLSX spreadsheet | |
| A-3 Price List - Sitagliptan-Metformin - Diabetes Non-Insulin - DPP-4 Inh.xlsx | XLSX spreadsheet | |
| A-3 Price List - Iqirvo - Gastrointestinal-2 Agents - NA.xlsx | XLSX spreadsheet | |
| A-3 RFQ HT9402-24-Q-9304 NAD.pdf | ||
| A-3 Price List - Duvyzat - Corticosteroids-Immune Mods - NA.xlsx | XLSX spreadsheet | |
| A-3 Price List - Tyenne - TIBS - Non-TNFI.xlsx | XLSX spreadsheet | |
| A-3 DoD Formulary Placement of FDA Newly Approved Drugs.pdf | ||
| A-3 Price Appendix FAQ NAD.pdf |
Show all 14
On GovTribe
Work with this file
- Download the original file
- Contacts named in this file
- Similar government files
- Ask GovTribe AI about this file
Text version
DEFENSE HEALTH AGENCY
7700 ARLINGTON BOULEVARD, SUITE 5101
FALLS CHURCH, VIRGINIA 22042-5101
HT9402-24-Q-9304 0003
July 10, 2024
SUBJECT: Amendment to Solicitation HT9402-24-Q-9304 to remove Fasenra 10mg – Atopy -
NA.
1. The purpose of this amendment is to remove Fasenra 10mg – Atopy - NA from RFQ
HT9402-24-Q-9304
2. All other terms and conditions remain the same.
Marsha L. Petersen Contracting Officer
| 2024-07-10T13:01:18-0500 | |
| PETERSEN.MARSHA.LISA.1021485299 |
File details come from the government source that posted it. Updated .